When a Medical Marijuana Prescription Is Really a Permission Slip

Texas wants the public to believe there are two fundamentally different kinds of THC. There is the dangerous kind sold by independent hemp businesses, and there is the respectable kind sold through the state’s Compassionate Use Program. One is treated like a public threat. The other is called medicine because a doctor entered a patient into a database.

The molecule does not know who sold it. A gummy does not become medicine because it came from a state-licensed operator. A vape does not become clinically precise because regulators call it pulmonary inhalation. The practical difference is who controls access and who gets paid.

A Prescription Without Much Prescribing

Real prescribing is more than permission. A clinician identifies the condition, weighs contraindications and drug interactions, chooses a starting dose, explains what success should look like, watches for side effects, and changes or stops the treatment when the evidence calls for it.

Ask those same questions about medical cannabis. What is the standard dose of THC for chronic pain? What is the dose for muscle spasticity? Should it change with age, psychiatric history, other medications, tolerance, or route of administration? At what point should the doctor decide it is not working?

Cannabis research can offer cautious starting ranges and titration strategies, but it has not produced one condition-specific dose that works across products and patients. The final federal evidence review on cannabinoids for chronic pain found small short-term benefits for some products, mostly in neuropathic pain, along with more dizziness, sedation, and nausea. Trials of spasticity have studied particular formulations under particular protocols. That is not the same as knowing what dose belongs on every Texas patient’s prescription.

Uncertainty is not proof that cannabis lacks medical value. It is a reason to demand more care from the system using medicine as its justification.

Texas' Own Review Found the Weak Point

A state-commissioned evaluation of the Compassionate Use Program said patients must have a treatment plan, but it also found no set term for prescription expiration and no requirement for regular consultations to review that plan. The report recommended guidance to better define the physician-patient relationship.

That finding matters more than the word prescription. If regular review is not required, the state cannot simply point to a doctor’s name in CURT and call the product supervised.

A responsible cannabis physician can do valuable work. The doctor can review medications, screen for psychosis risk, talk honestly about impairment, help a patient start low, and stop treatment that causes harm. The problem is that Texas uses physician involvement to defend the entire market without requiring every encounter to deliver that level of care.

The Money-Back Approval Model

The sales pitch makes the incentive hard to ignore. Some Texas cannabis clinics advertise an online consultation, CURT enrollment, a year of certification, and a full refund if the patient is not approved. Patients can pay extra for another appointment when they want dose changes between annual certifications.

A refund policy is not proof that a doctor is acting improperly. It does create a plain conflict in the business model. The clinic gets paid when the patient qualifies and earns nothing when the patient is denied. Approval can also create a returning customer for renewals and adjustments.

That is why Texas should publish the numbers. How many paying applicants are approved? How long is the average visit? How many are rejected? How often are outside medical records verified? How many patients receive a documented mental-health or substance-use screening? How often does a physician lower a limit, decline inhalation, or end treatment?

Without those answers, doctor-supervised is a marketing phrase, not a demonstrated standard.

It Looks Like Ordering a GLP-1 Online, Except the Dose Is Missing

The closest mainstream comparison is the online GLP-1 clinic. A patient fills out a questionnaire, uploads health information, pays, meets a clinician by video or messaging, and may receive a prescription without entering a traditional office. The convenience is real, and so are the financial incentives. Federal regulators have warned telehealth companies about misleading promotion and dosing mistakes involving compounded semaglutide.

But an FDA-approved GLP-1 such as Wegovy still comes with a defined clinical framework. The label sets a 0.25 milligram weekly starting dose, increases it on a four-week schedule, identifies maintenance doses, lists contraindications, and tells clinicians what to monitor. Weight, blood glucose, adverse effects, and treatment response give the prescriber measurable information.

Texas cannabis clinics may be just as easy to access, but where is the comparable protocol? What measurable result determines whether five milligrams of THC becomes ten? What clinical threshold supports a higher monthly limit? If the answer is mainly that the patient says more is needed, the physician is not selecting a dose in the ordinary meaning of prescribing. The physician is documenting the patient’s request.

The GLP-1 market has its own serious problems, especially when compounded products are marketed as if they were FDA-approved. Still, the comparison exposes the weakness in Texas’ argument. Telehealth is not the issue. Thin clinical standards are.

Medicine at the Dispensary, Menace at the Hemp Shop

Texas permits medical cannabis gummies and other edibles. Its program review found edibles were the most popular format among surveyed patients. The state also allows a qualifying physician to prescribe pulmonary inhalation through an approved device.

So gummies are not inherently illegitimate. Vaporized THC is not categorically unacceptable. THC does not change identity when it moves from a hemp retailer to a licensed medical dispensary.

Yet at a July 2026 Texas Senate hearing, an invited witness called THC a weapon of mass destruction while comparing it with fentanyl. That language is not a serious basis for public-health policy. THC carries real risks, including impairment, dependence, accidental child exposure, and psychiatric harm for susceptible people. Those risks support age limits, testing, honest labels, child-resistant packaging, advertising restrictions, and enforcement against bad actors.

They do not justify describing THC as catastrophic outside the state program while treating the same intoxicant as safe after a paid telehealth visit.

Regulatory Capture Dressed as Compassion

Texas spent years limiting its medical market to a tiny group of licensed dispensing organizations. Independent hemp farmers, manufacturers, and retailers then built a wider market that competed for many of the same consumers. As lawmakers moved to restrict hemp, they expanded medical access, added product formats, and created more room for the state-selected channel.

That pattern has the shape of regulatory capture. Restrict the competing market. Raise compliance costs. Confer medical legitimacy on a protected group. Insert a paid gatekeeper between the consumer and the product. Then describe businesses outside the system as a danger that must be removed.

That is not prohibition. It is a transfer of customers.

People using THC for pain, sleep, or PTSD symptoms do not vanish when a hemp store closes. They move into the medical program, buy from an illicit source, travel, or go without. Certification clinics gain appointments. Licensed dispensaries gain sales. Small businesses without a place in the state program lose their livelihood.

If It Is Medicine, Regulate the Medical Care

Texas cannot use a doctor as the entire moral defense of medical cannabis while treating that doctor as a one-time toll booth. If physician involvement is what makes the market safer, the state should require it to mean something.

• Document the diagnosis, baseline symptoms, and measurable treatment goals.
• Record a starting dose and explain the evidence or clinical reasoning behind it.
• Screen for psychiatric risk, substance-use disorder, pregnancy, drug interactions, and impairment concerns.
• Require scheduled follow-up before automatic annual renewal.
• Audit high-volume clinics and publish approval, denial, and adverse-event data.
• Require documented reasoning for major quantity increases and inhaled products.
• Separate payment from approval so denial does not erase the clinic’s fee.

Hemp should face serious product rules too. Texas can require adult-only sales, independent testing, contaminant limits, accurate milligram labels, child-resistant packages, and marketing standards without wiping out independent operators.

The state should regulate risk, not ownership. A paid authorization is not automatically a treatment plan. A CURT entry is not proof of continuing supervision. When Texas condemns THC in the open market while building a protected channel around the same products, medical marijuana starts to look less like a health policy and more like the state’s newest pay-to-play franchise.

Sources and Further Reading

• Texas Compassionate Use Program evaluation and recommendations
• Texas DPS patient process and CURT information
• Texas rules for pulmonary inhalation devices
• Updated systematic review of cannabis-based products for chronic pain
• FDA prescribing information for Wegovy
• FDA concerns about unapproved GLP-1 products and telehealth dosing
• Coverage of the July 2026 Texas Senate THC hearing